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Background
Aims
Results
• 12 healthy adult males received three treatments in a crossover design (Figure 1)
• Apixaban plasma concentration was determined using a validated LC-MS/MS assay
Discussion
Conclusion
• The confidence interval for only Cmax, but not AUC0-tlast or AUC0-∞, lay completely 
above 1, indicating that overall apixaban exposure is unaffected when coadministered
with cyclosporine
• The observed change in apixaban exposure with cyclosporine reflects the effect of 
combined inhibition of P-gp and BCRP transporter-mediated efflux as well as 
CYP3A4 metabolism
• The CI for both AUC0-tlast and AUC0-∞, but not Cmax, lay completely below 1, suggesting 
a small decrease in apixaban exposure when comedicated with tacrolimus
• The observed decrease in apixaban exposure with tacrolimus was unexpected. The 
inhibitory potency of tacrolimus on P-gp, BCRP transporters is not well characterized
• In the absence of potent inhibitory activity at the transporters, the coadministration 
of apixaban and tacrolimus, could potentially result in a competitive inhibition of 
transporter-mediated efflux, contributing to increased efflux and elimination of 
apixaban
• The change in apixaban exposure with cyclosporine or tacrolimus is not expected to 
meaningfully alter the safety and efficacy of apixaban based on the magnitude of 
other drug interactions listed in the product label
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Figure 1: Study Design
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Table 1. Subject Characteristics
• Apixaban is a direct factor Xa inhibitor approved for treatment of venous 
thromboembolism (VTE)
• It is metabolized by the CYP3A4, and is a substrate to the permeability glycoprotein 
(P-gp) and breast cancer resistance protein (BCRP) transporters
• The combined use of apixaban with a strong dual inhibitor of P-gp and CYP3A4 such 
as ketoconazole results in a 2-fold increase in apixaban exposure necessitating dose 
adjustment
• Cyclosporine and tacrolimus are indicated for prophylaxis of organ rejection in 
patients receiving allogeneic renal, cardiac, or hepatic transplants
• Cyclosporine is a weak inhibitor of CYP3A4 and potent inhibitor of both P-gp, BCRP
• Tacrolimus is believed to share overlapping inhibitor activity on these pathways but 
is considered a weaker inhibitor than cyclosporine
• Thus, concentrations of apixaban may potentially increase in transplant patients 
comedicated with calcineurin inhibitors
• To determine the effect of 100mg cyclosporine administered daily for 3 days on the 
pharmacokinetic parameters of apixaban following coadministration of a single oral 
dose of 10 mg to healthy volunteers
• To determine the effect of 5mg tacrolimus administered daily for 3 days on the 
pharmacokinetic parameters of apixaban following coadministration of a single oral 
dose of 10 mg to healthy volunteers
• Pharmacokinetic (PK) parameters included AUC0-tlast, AUC0-∞, Cmax, Tmax, and 
apparent terminal t1/2
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Subject Demographics
Number of Subjects (N=12), n (%)
Male 12 (100.0)
Age (yr)
Range
41
25-54
BMI (Kg/m2), range 24-33
Race
Black or African American
White
9 (75)
3 (25)
Apixaban Pharmacokinetic Interaction with Cyclosporine 
and Tacrolimus
• The concentration-time profile of 10 mg apixaban alone was compared to the 
concentration-time profile of 10 mg apixaban when cyclosporine (Figure 2A) or 
tacrolimus (Figure 2B) was coadministered
• The apixaban plasma concentration reached its peak (Tmax) at 2.5 hours postdose
• All subjects had no quantifiable predose concentrations of apixaban on day 1 of each 
treatment period. All subjects had quantifiable plasma apixaban concentrations up to 
24 hours postdose
• Summary statistical comparison of PK parameters from subjects administered 10 mg 
apixaban alone compared to apixaban with cyclosporine and tacrolimus 
coadministration is presented in Table 2
Figure 2. Apixaban plasma concentration-time profile with 
Cyclosporine (A) and Tacrolimus (B)
A B
Table 2. Summary Pharmacokinetic Parameters
Apixaban 
alone
Cyclosporine DDI Study Tacrolimus DDI Study
PK Parameter Geometric 
mean (90% CI)
Geometric 
mean (90% CI)
GMR (90% CI) Geometric 
mean (90% CI)
GMR (90% CI)
Cmax (ng mL-1) 179
(147, 219)
257
(211, 311)
1.43
(1.12, 1.83)
157
(129, 191)
0.87
(0.67, 1.12)
AUC0-tlast (h ng 
mL-1)
1684
(1427, 1987)
2018
(1710, 2381)
1.20
(0.97, 1.48)
1318
(1117, 1555)
0.78
(0.63, 0.97)
AUC0-∞ (h ng mL-1) 1875
(1619, 2172)
2237
(1931, 2591)
1.19
(0.99, 1.44)
1448
(1251, 1678)
0.77
(0.64, 0.93)
Tmax (h) 2.5 
[1, 4]
2.5
[1, 4]
- 2.5
[1, 4]
-
t1/2 (h) 6.5 (3)
[3.4, 12.6]
5.2 (1.8)
[3.3, 10]
- 7.0 (1.9)
[5,11]
-
CI=confidence interval, DDI=drug-drug interaction, PK=pharmacokinetics, GMR=geometric least-squares mean ratio between treatments
Back-transformed least-squares mean and CI was derived from linear mixed-effects model performed on natural log-transformed values 
adjusting for the random effect of subject and the fixed effect of the sequence
• Multiple-dose administration of 100 mg cyclosporine or 5 mg tacrolimus daily with a 
single dose of 10 mg apixaban was generally well tolerated by the healthy subjects in 
the study
• Coadministration of cyclosporine or tacrolimus and apixaban had no clinically 
meaningful effect on the PK of apixaban
• Apixaban and cyclosporine or tacrolimus may be coadminstered without dose 
adjustment
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